查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
驅蟲藥市場：按藥物類別、感染類型和分銷管道分類：2023-2032 年全球機會分析和產業預測
市場調查報告書
商品編碼
1414815

驅蟲藥市場：按藥物類別、感染類型和分銷管道分類：2023-2032 年全球機會分析和產業預測

Anthelmintic Drugs Market By Drug Class, By Infection Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

由於製藥業市場需求的增加，2023年至2032年驅蟲藥市場可能會出現3.8%的顯著成長率。

驅蟲藥市場-IMG1

由於寄生蟲感染疾病在全球範圍內流行，影響了全世界數百萬人，因此驅蟲藥在全球衛生工作中發揮重要作用。這些感染疾病是由線蟲、圓線蟲和絛蟲引起的，在衛生條件差和醫療保健條件差的國家尤其普遍。許多開發中國家盛行土源性 (STH) 蠕蟲，例如：

1 蛔蟲、鞭蟲和鉤蟲普遍存在。這些感染疾病會導致嚴重的健康問題，尤其是兒童，影響生長、認知和生活品質。

例如，根據美國國家生物技術資訊中心（NCBI）2021年發表的論文通報，全球整體約有350萬人遭受腸道寄生蟲感染疾病，每年有超過20萬人死亡。此類寄生蟲感染疾病的發生增加了對驅蟲藥的需求並推動了市場成長。此外，還有一些通用感染疾病可以從動物傳播給人類，並可能導致嚴重的健康問題，例如：

1 香港腳，足癬的併發症。對抗這些感染疾病不僅造福個人，也有利於當地社區的福祉，提高經濟生產力，並改善生活品質。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 寄生蟲感染疾病增加
      • 提高對蠕蟲感染疾病預防措施的認知
      • 學名藥的可得性
    • 抑制因素
      • 驅蟲藥高成本
      • 缺乏對感染疾病的認知與教育
    • 機會
      • 新興市場的成長機會

第4章驅蟲藥市場：依藥物類別

  • 概述
  • 苯並咪唑
  • 大環內酯
  • 奎諾酮
  • 四氫嘧啶
  • 其他

第5章驅蟲藥市場：依感染類型

  • 概述
  • 絛蟲感染疾病
  • 線蟲感染疾病
  • 線蟲感染疾病
  • 混合感染

第6章驅蟲藥市場：依通路分類

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第7章驅蟲藥市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Reese Pharmaceutical Company
  • Amneal Pharmaceuticals LLC
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Bayer AG
  • Cipla Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
Product Code: A11501

The anthelmintic drugs market is likely to experience a significant growth rate of 3.8% from 2023-2032 owing to increasing market demand from pharmaceuticals sector - Allied Market Research

Anthelmintic Drugs Market - IMG1

Anthelmintic drugs play an essential role in global health initiatives due to the global prevalence of parasitic worm infections, which affect millions of people around the globe. These infections are caused by nematode, trematode, and cestode, and are particularly prevalent in countries with poor sanitation and lack of access to healthcare. In many developing countries, soil-transmitted (STH) helminths such as roundworm, whipworm, and hookworm are endemic. These infections cause serious health problems, particularly in children, which can affect their growth, cognition, and quality of life.

For instance, according to an article published by National Centre for Biotechnology Information (NCBI) in 2021, globally there are around 3.5 million people affected with intestinal parasitic infections, and more than 200,000 deaths are reported annually. Such incidences of such parasitic infections are increasing the need for anthelmintic, which propels the market growth. In addition, there are also zoonotic infections, which are transmitted by animals to humans and can lead to serious health problems, such as hydatid disease which is a complication of the tapeworm. Combating these infections not only benefits the individual, but also contributes to the well-being of the community, increases economic productivity, and improves the quality of life.

In addition, there is an increase in government expenditure and investment in healthcare infrastructure, including the allocation of funds to treat and prevent various diseases, such as parasitic worm infections, owing to economic growth in emerging economies. There is an increase in availability of affordable and accessible anthelmintic drug for the population owing to increased financial resources for healthcare. Economic growth often leads to improved access to healthcare facilities, such as clinics, hospitals and pharmacies. This improved accessibility means that people living in rural or poor areas, where the prevalence of parasitic infections may be higher, can now visit healthcare facilities to be diagnosed and treated for these conditions. The demand for anthelmintic drugs increases as more people can access healthcare facilities.

The anthelmintic drugs market is segmented on the basis of drug class, infection type, distribution channel, and region. On the basis of drug class, the market is divided into benzimidazoles, macrocyclic lactones, pyrazinoisoquinolones, tetrahydropyrimidines and others. On the basis of infection type, the market is classified into nematode infections, cestode infections, trematode infections and mixed infections. Based on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.

Major players profiled in this report are GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Bayer AG, Cipla Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Reese Pharmaceutical Company, and Zydus Lifesciences Limited.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anthelmintic drugs market analysis from 2022 to 2032 to identify the prevailing anthelmintic drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the anthelmintic drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global anthelmintic drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Drug Class

  • Benzimidazoles
  • Macrocyclic Lactones
  • Pyrazinoisoquinolones
  • Tetrahydropyrimidines
  • Others

By Infection Type

  • Cestode Infections
  • Nematode Infections
  • Trematode Infections
  • Mixed Infections

By Distribution Channel

  • Online Providers
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Cipla Ltd.
    • Teva Pharmaceutical Industries Limited
    • Zydus Lifesciences Limited
    • Amneal Pharmaceuticals LLC
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Reese Pharmaceutical Company
    • Bayer AG

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rising incidences of parasitic infections
      • 3.4.1.2. Growing awareness of preventive measures against helminth infections
      • 3.4.1.3. Availability of generic medications
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of anthelmintic drugs
      • 3.4.2.2. Lack of awareness and education about infectious diseases
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets

CHAPTER 4: ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Benzimidazoles
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Macrocyclic Lactones
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Pyrazinoisoquinolones
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Tetrahydropyrimidines
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Cestode Infections
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Nematode Infections
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Trematode Infections
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Mixed Infections
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ANTHELMINTIC DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Infection Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Drug Class
      • 7.2.5.1.2. Market size and forecast, by Infection Type
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Drug Class
      • 7.2.5.2.2. Market size and forecast, by Infection Type
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Drug Class
      • 7.2.5.3.2. Market size and forecast, by Infection Type
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Infection Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Drug Class
      • 7.3.5.1.2. Market size and forecast, by Infection Type
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Drug Class
      • 7.3.5.2.2. Market size and forecast, by Infection Type
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Drug Class
      • 7.3.5.3.2. Market size and forecast, by Infection Type
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Drug Class
      • 7.3.5.4.2. Market size and forecast, by Infection Type
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Drug Class
      • 7.3.5.5.2. Market size and forecast, by Infection Type
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Drug Class
      • 7.3.5.6.2. Market size and forecast, by Infection Type
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Infection Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Drug Class
      • 7.4.5.1.2. Market size and forecast, by Infection Type
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Drug Class
      • 7.4.5.2.2. Market size and forecast, by Infection Type
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Drug Class
      • 7.4.5.3.2. Market size and forecast, by Infection Type
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Drug Class
      • 7.4.5.4.2. Market size and forecast, by Infection Type
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Drug Class
      • 7.4.5.5.2. Market size and forecast, by Infection Type
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Drug Class
      • 7.4.5.6.2. Market size and forecast, by Infection Type
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Infection Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Drug Class
      • 7.5.5.1.2. Market size and forecast, by Infection Type
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Drug Class
      • 7.5.5.2.2. Market size and forecast, by Infection Type
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Drug Class
      • 7.5.5.3.2. Market size and forecast, by Infection Type
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Drug Class
      • 7.5.5.4.2. Market size and forecast, by Infection Type
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Reese Pharmaceutical Company
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
  • 9.2. Amneal Pharmaceuticals LLC
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. GlaxoSmithKline plc
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Johnson & Johnson
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Merck & Co., Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Bayer AG
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Cipla Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Sun Pharmaceutical Industries Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Zydus Lifesciences Limited
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. ANTHELMINTIC DRUGS MARKET FOR BENZIMIDAZOLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. ANTHELMINTIC DRUGS MARKET FOR MACROCYCLIC LACTONES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. ANTHELMINTIC DRUGS MARKET FOR PYRAZINOISOQUINOLONES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. ANTHELMINTIC DRUGS MARKET FOR TETRAHYDROPYRIMIDINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. ANTHELMINTIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 08. ANTHELMINTIC DRUGS MARKET FOR CESTODE INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. ANTHELMINTIC DRUGS MARKET FOR NEMATODE INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ANTHELMINTIC DRUGS MARKET FOR TREMATODE INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ANTHELMINTIC DRUGS MARKET FOR MIXED INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 13. ANTHELMINTIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. ANTHELMINTIC DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. ANTHELMINTIC DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. ANTHELMINTIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA ANTHELMINTIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. U.S. ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 22. U.S. ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. CANADA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 25. CANADA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 26. CANADA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE ANTHELMINTIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. UK ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. UK ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 42. UK ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. ITALY ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 44. ITALY ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 45. ITALY ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. CHINA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. CHINA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 61. CHINA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. INDIA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 63. INDIA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 64. INDIA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. LAMEA ANTHELMINTIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 83. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. REESE PHARMACEUTICAL COMPANY: KEY EXECUTIVES
  • TABLE 91. REESE PHARMACEUTICAL COMPANY: COMPANY SNAPSHOT
  • TABLE 92. REESE PHARMACEUTICAL COMPANY: PRODUCT SEGMENTS
  • TABLE 93. REESE PHARMACEUTICAL COMPANY: PRODUCT PORTFOLIO
  • TABLE 94. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 95. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 96. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 97. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 98. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 99. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 100. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 101. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 102. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 103. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 104. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 105. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 106. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 107. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 108. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 109. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 110. BAYER AG: KEY EXECUTIVES
  • TABLE 111. BAYER AG: COMPANY SNAPSHOT
  • TABLE 112. BAYER AG: PRODUCT SEGMENTS
  • TABLE 113. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 114. CIPLA LTD.: KEY EXECUTIVES
  • TABLE 115. CIPLA LTD.: COMPANY SNAPSHOT
  • TABLE 116. CIPLA LTD.: PRODUCT SEGMENTS
  • TABLE 117. CIPLA LTD.: PRODUCT PORTFOLIO
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 121. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 126. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 127. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 128. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 129. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ANTHELMINTIC DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTHELMINTIC DRUGS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN ANTHELMINTIC DRUGS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN ANTHELMINTIC DRUGS MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL ANTHELMINTIC DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. ANTHELMINTIC DRUGS MARKET, BY DRUG CLASS, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR BENZIMIDAZOLES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR MACROCYCLIC LACTONES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR PYRAZINOISOQUINOLONES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR TETRAHYDROPYRIMIDINES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. ANTHELMINTIC DRUGS MARKET, BY INFECTION TYPE, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR CESTODE INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR NEMATODE INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR TREMATODE INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR MIXED INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. ANTHELMINTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF ANTHELMINTIC DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. ANTHELMINTIC DRUGS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 27. U.S. ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. CANADA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MEXICO ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. GERMANY ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. FRANCE ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. ITALY ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF EUROPE ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. JAPAN ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. INDIA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. AUSTRALIA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. BRAZIL ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF LAMEA ANTHELMINTIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50. COMPETITIVE DASHBOARD
  • FIGURE 51. COMPETITIVE HEATMAP: ANTHELMINTIC DRUGS MARKET
  • FIGURE 52. TOP PLAYER POSITIONING, 2022
  • FIGURE 53. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. CIPLA LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. CIPLA LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. CIPLA LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 72. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 74. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 76. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)